Catalyst Wire Dossier Catalyst Wire Dossier

tiotropium + olodaterol fixed-dose combination (5 μg/5 μg)

· Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for tiotropium + olodaterol fixed-dose combination (5 μg/5 μg), covering 2019-03-29 to 2019-03-29. Get the full timeline:

Most recent: Clinical Trial Update: Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients [Phase 1]

See pricing